Paragon 28 Beheer

Beheer criteriumcontroles 3/4

De CEO Paragon 28 is Albert DaCosta, benoemd in Jan2012, heeft een ambtstermijn van 12.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.23M, bestaande uit 21.7% salaris en 78.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 13.2% van de aandelen van het bedrijf, ter waarde € 105.75M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 3.4 jaar.

Belangrijke informatie

Albert DaCosta

Algemeen directeur

US$3.2m

Totale compensatie

Percentage CEO-salaris	21.7%
Dienstverband CEO	12.8yrs
Eigendom CEO	13.2%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Albert DaCosta's beloning veranderd ten opzichte van Paragon 28's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$56m
Jun 30 2024	n/a	n/a	-US$55m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$3m	US$701k	-US$48m
Sep 30 2023	n/a	n/a	-US$74m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$5m	US$650k	-US$67m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$5m	US$615k	-US$14m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	n/a	n/a	US$4m
Dec 31 2020	US$933k	US$588k	US$3m

Compensatie versus markt: De totale vergoeding ($USD 3.23M ) Albert } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.44M ).

Compensatie versus inkomsten: De vergoeding van Albert is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Albert DaCosta (51 yo)

12.8yrs

Tenure

US$3,232,421

Compensatie

Mr. Albert DaCosta is Co-Founder of Paragon 28, Inc. and serves as Chief Executive Officer, President and Director since 2012. Mr. DaCosta is a veteran in the foot and ankle industry with over 18 years of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Albert DaCosta	Co-Founder	12.8yrs	US$3.23m	13.2% € 105.8m
Robert McCormack	General Counsel & Secretary	1.3yrs	US$1.40m	0.0092% € 73.9k
Matthew Jarboe	Executive VP of Sales & Chief Commercial Officer	6.8yrs	US$1.53m	0.27% € 2.2m
Andrew Hill	Executive Vice President of Research & Development	1.1yrs	US$1.31m	0.091% € 731.9k
Chadi Chahine	CFO & Executive VP of Supply Chain Operations	less than a year	geen gegevens	0.00040% € 3.2k
Matthew Brinckman	Senior Vice President of Strategy & Investor Relations	2.3yrs	geen gegevens	geen gegevens
Brendan Shook	Executive VP of Marketing & Medical Education	5.2yrs	geen gegevens	geen gegevens
Matthew Millard	Chief Human Resources Officer	1.7yrs	geen gegevens	geen gegevens
John Shumaker	Executive Vice President of Sales - U.S.	3.8yrs	geen gegevens	geen gegevens
Hans Kestler	Executive Vice President of International	4.3yrs	geen gegevens	geen gegevens
Yuliya Aslan	Senior Vice President of IT	3.8yrs	geen gegevens	geen gegevens
Sanket Shah	Senior VP	1.1yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 7GQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Albert DaCosta	Co-Founder	12.8yrs	US$3.23m	13.2% € 105.8m
B. Johnson	Independent Director	2.9yrs	US$212.50k	0.032% € 255.6k
Stephen Newman Oesterle	Independent Director	3.8yrs	US$210.00k	0.029% € 232.6k
Thomas Schnettler	Lead Independent Director	4.3yrs	US$245.00k	0.027% € 218.9k
Quentin Blackford	Independent Director	2.3yrs	US$220.00k	0.028% € 227.6k
Meghan Scanlon	Independent Director	2.6yrs	US$210.61k	0.024% € 193.8k
Alf Grunwald	Independent Director	7.8yrs	US$210.00k	0.036% € 284.9k
Kristina Wright	Director	2.9yrs	US$220.00k	0.022% € 177.6k

3.4yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 7GQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Paragon 28 Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Co-Founder recently bought €234k worth of stock

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

High number of new directors

Insider recently sold €1.1m worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023)

Paragon 28, Inc. Raises Net Revenue Guidance for 2024

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc

Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc

Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

Rosen Law Firm Files Securities Class Action Lawsuit Against Paragon 28, Inc

Paragon 28, Inc. Launches the R3FLEX™? Stabilization System to Anatomically Repair Ankle Syndesmotic In Injury

Paragon 28, Inc. Announces the Launch of SMART28 Case Management Portal

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2023)

Paragon 28, Inc. Updates Revenue Guidance for the Full Year of 2024

Paragon 28, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2023)

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought €234k worth of stock

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.88 loss in FY 2022)

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

New minor risk - Share price stability

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2022)

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.26 loss in FY 2021)

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 3Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold €1.1m worth of stock

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Paragon 28, Inc. Announces Board Changes

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.05 loss in 2Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022

Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index

Key Executive recently sold €355k worth of stock

Paragon 28, Inc. Launches Monkey Rings™ Circular External Fixation System

Key Executive recently sold €420k worth of stock

Paragon 28, Inc. Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.021 loss in 1Q 2021)

Paragon 28, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new directors

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

Paragon 28, Inc. Launches R3ACT™ Stabilization System for Ankle Injuries

Paragon 28, Inc. to Report Q1, 2022 Results on May 09, 2022

Paragon 28, Inc. Announces Executive Changes